The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Open accessAbstract
BACKGROUND: -positive NSCLC is unclear. METHODS: -positive NSCLC who had received no previous systemic treatment for metastatic disease. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included independently assessed objective response and intracranial response. An interim analysis of efficacy was planned after approximately 133 of 177 (75%) expected events of disease progression or death had occurred. RESULTS: The percentage of patients who were alive without disease progression at 12 months was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P<0.001). An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lorlatinib group and 58% (95% CI, 49 to 66) of those in the crizotinib group; among those with measurable brain metastases, 82% (95% CI, 57 to 96) and 23% (95% CI, 5 to 54), respectively, had an intracranial response, and 71% of the patients who received lorlatinib had an intracranial complete response. The most common adverse events with lorlatinib were hyperlipidemia, edema, increased weight, peripheral neuropathy, and cognitive effects. Lorlatinib was associated with more grade 3 or 4 adverse events (mainly altered lipid levels) than crizotinib (in 72% vs. 56%). Discontinuation of treatment because of adverse events occurred in 7% and 9% of the patients, respectively. CONCLUSIONS: -positive NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib. The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels. (Funded by Pfizer; CROWN ClinicalTrials.gov number, NCT03052608.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,148
Self-citationBrigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Self-citationLong, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791
Self-citationShaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S., Gainor, J. F., Johnson, M., Dietrich, J., James, L. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30680-0 · Cited by 659
Self-citationCSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 596
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
Camidge, D. R., Dziadziuszko, R., Peters, S., Mok, T., Noe, J., Nowicka, M., Gadgeel, S. M., Cheema, P., Pavlakis, N., de Marinis, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.007 · Cited by 490
Self-citationZou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.010 · Cited by 471
Self-citationShaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C.-C., Soo, R. A., Riely, G. J., Ou, S.-H. I., Clancy, J. S., Li, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02236 · Cited by 383
Self-citationShaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C.-C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 358
Self-citationCamidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., Lee, K. H., Delmonte, A., García Campelo, M. R., Kim, D.-W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00505 · Cited by 351
Self-citationTRK inhibitors in TRK fusion-positive cancers
Drilon, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz282 · Cited by 291
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Katayama, R., Friboulet, L., Koike, S., Lockerman, E. L., Khan, T. M., Gainor, J. F., Iafrate, A. J., Takeuchi, K., Taiji, M., Okuno, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1511 · Cited by 290
Self-citationSurvival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases
Ali, A., Goffin, J. R., Arnold, A., & Ellis, P. M. (2013) · Current Oncology · doi:10.3747/co.20.1481 · Cited by 235
Horn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Leal, T. A., Du, L., Hernandez, J., Huang, V., Blumenschein, G. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.003 · Cited by 171
Clinical Management of Adverse Events Associated with Lorlatinib
Bauer, T. M., Felip, E., Solomon, B. J., Thurm, H., Peltz, G., Chioda, M. D., & Shaw, A. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0380 · Cited by 166
Self-citationBauer, T. M., Shaw, A. T., Johnson, M. L., Navarro, A., Gainor, J. F., Thurm, H. C., Pithavala, Y. K., Abbattista, A., Peltz, G., & Felip, E. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00702-4 · Cited by 122
Self-citationGainor, J. F., Chi, A. S., Logan, J., Hu, R., Oh, K. S., Brastianos, P. K., Shih, H. A., & Shaw, A. T. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.010 · Cited by 74
Self-citationReed, M. L., Rosales, A.-L. S., Chioda, M. D., Parker, L., Devgan, G., & Kettle, J. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01365-3 · Cited by 60
Targeted Therapy in Brain Metastases: Ready for Primetime?
Venur, V. A., & Ahluwalia, M. S. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100006 · Cited by 57
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Metadata
- Authors
- Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., & Solomon, B. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-19
- Volume
- 383
- Issue
- 21
- Pages
- 2018-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3101089668
- Cited by
- 1,099
- References
- 28
- FWCI
- 70.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.